查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836973

RNA療法市場按治療領域、給藥系統和最終用戶分類－2025-2032年全球預測

RNA Therapy Market by Therapeutic Area, Delivery System, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，RNA 療法市場將成長至 141.5 億美元，複合年成長率為 23.55%。

主要市場統計數據
基準年2024年 26億美元
預計年份：2025年 32.3億美元
預測年份：2032年 141.5億美元
複合年成長率 (%) 23.55%

這是一份全面的入門指南，闡述了RNA療法、遞送創新和監管演變的進展如何匯聚在一起，重新定義治療藥物的研發管道。

RNA療法領域已從科學探索轉變為現代生物醫學的核心支柱，重塑了研究人員、臨床醫生和行業領袖開展治療方法發現和開發的方式。傳訊RNA、小干擾RNA、反義寡核苷酸及相關方法的進步，在廣泛的適應症領域展現出治療潛力，刺激了對平台技術、遞送系統和專業生產能力的新投資。這種轉變體現在加速的轉化研究、產研策略合作以及對可擴展、可重複生產流程日益重視等。

技術日趨成熟，加之監管預期和臨床證據要求不斷變化，迫使研發人員改善臨床研究設計、安全性監測方法和對照藥物選擇。同時，遞送載體、製劑化學和分析方法的改進降低了新研發人員的進入門檻，同時也提高了產品差異化的標準。因此，企業現在優先考慮平台穩健性、跨適應症適用性以及在不同患者群體中展現一致性療效的能力。

在相關人員評估後續步驟之際，該產業必須將科學進展與切實可行的營運計畫結合。如今，生產能力、供應鏈韌性和監管參與與標靶選擇和臨床前療效同等重要。簡而言之，RNA療法正處於一個關鍵的十字路口，科學前景必須與卓越的執行力相契合，才能轉化為持續的臨床和商業性成功。

深入分析遞送平台、臨床優先排序和經營模式的突破如何重塑RNA療法生態系統和商業化策略。

RNA療法領域正經歷一系列變革時期，這些變革正在改變研發者和投資者的策略重點。基於脂質奈米顆粒的製劑和新興的外泌體平台實現了以往難以實現的全身遞送和組織靶向，而聚合物載體和病毒載體雜交體則為持續表達和局部療效提供了互補的途徑。這些遞送技術的進步拓展了可治療的適應症，影響了給藥模式，並對生產要求產生了重大影響。

其次，臨床關注明顯轉向複雜且以往難以治療的疾病，而罕見疾病治療則正利用基因靜默和基因替代策略來應對高雪氏症、神經肌肉疾病和鐮狀細胞疾病等遺傳性疾病。由於全球公共衛生優先事項以及RNA平台能夠實現的快速反應，感染疾病應用，包括針對病毒感染的標靶療法和新型抗菌RNA策略，仍具有重要的策略意義。

第三，隨著以平台為中心的公司尋求透過授權、策略聯盟和垂直整合來實現廣泛的技術堆疊的收益，經營模式正在轉變。合約開發和受託製造公司正在擴展其能力，以應對高濃度製劑和脂質奈米顆粒封裝等問題；隨著臨床給藥模式的演變，醫院和診所也以新的方式應用先進療法。研究機構持續推動創新，建構了一個充滿活力的創新管道，各部門之間的相互依存度日益增強。

最後，監管機構和支付方對證據的日益重視正在重塑打入市場策略。研發人員正投資於真實世界證據的產生、長期安全性監測和衛生經濟學研究，以支持報銷討論和政策制定。總而言之，這些轉變標誌著RNA療法正從孤立的概念驗證工作轉向持續的、系統性的臨床實踐整合。

對關稅如何改變RNA治療項目的供應鏈、籌資策略、臨床優先順序和生產投資進行詳細評估

美國可能在2025年實施的累積關稅，將為RNA療法相關企業帶來複雜的營運和策略挑戰。關稅政策的發展可能會增加脂質、核苷酸、酵素和一次性耗材等關鍵原料的到岸成本，並可能影響質體生產、微流體封裝、層析法系統和無菌填充生產線等高價值資本設備的供應和定價。不斷上漲的採購成本將迫使研發企業和契約製造製造商重新評估供應商關係、庫存策略和採購地域，以確保專案按時完成並達到品質標準。

為了因應關稅主導的成本壓力，企業可能會加快供應鏈在地化進程，擴大關鍵投入品的國內生產，或透過談判達成長期採購協議來穩定價格。雖然本地化可以降低跨境關稅的影響，但通常需要大量的資本投入和較長的營運前置作業時間，尤其是在需要特殊製造流程或監管核准的情況下。因此，缺乏內部製造能力的小型開發商和研發機構可能會受到不成比例的影響，迫使它們更多地依賴本地契約製造和戰略合作夥伴。

關稅也可能影響臨床開發決策。投入成本的增加可能促使申辦者最佳化試驗方案以減少每位患者的材料用量，優先考慮報銷途徑更明確的適應症，或根據資源密集程度調整項目順序。對於醫院和診所而言，這可能會加重採購預算負擔，並影響需要複雜交付和支援基礎設施的先進治療方法的推廣週期。投資者和策略合作夥伴可能會仔細審查供應鏈計劃的韌性以及在成本結構變化下擴大生產規模的可行性。

最後，與關稅政策相關的政治和監管訊號可能具有聲譽和戰略意義。貿易緊張局勢加劇可能促使跨國公司將製造地分散到多個地區，以避免受到單一地區政策變化的影響。同時，雙邊和多邊對話可能為關鍵醫療用品的豁免和關稅減免鋪平道路，凸顯了積極與政策制定者和行業協會溝通的重要性。簡而言之，2025年的關稅發展可能促使採購、生產策略、臨床項目優先順序等方面進行結構性調整，並對時間表和夥伴關係模式產生實際影響。

對治療領域差異、遞送平台權衡以及最終用戶行為的嚴格審查將確定RNA干預措施的項目管道和開發重點。

細分領域的動態揭示了科學機會與商業性可行性的交匯點，闡明了企業在推進基於RNA的干涉措施時必須面對的戰術性選擇。在分析治療領域細分時，研發人員需要在廣泛的適用性和特定適應症的複雜性之間取得平衡。心血管和代謝疾病計畫追求全身給藥和持續活性；遺傳疾病療法旨在針對一次性疾病進行精準的基因校正或定序；感染疾病策略區分細菌和病毒療法；神經病學計畫致力於解決血腦屏障的給藥限制；而罕見疾病則專注於特定疾病，例如高雪氏症、神經肌肉疾病和鐮狀細胞病，這些疾病的臨床終點和監管管道需要客製化化的證據包裝。這種血腦障壁的異質性也導致了不同的研發時間表、安全性考量和商業性准入策略。

從遞送系統細分的角度來看，這種對比更加鮮明。基於外泌體的策略有望實現生物天然遞送和潛在的免疫隱蔽性，但其生產和表徵面臨挑戰，需要先進的分析能力。脂質奈米顆粒技術因其已證實的可擴展性和成熟的監管先例，已成為許多系統性應用的實際解決方案，但需要嚴格控制輔料和過程參數。另一方面，病毒載體能夠為某些應用實現穩健的基因轉移，但補償是免疫抗原性和複雜的監管審查。遞送平台的選擇不僅影響臨床療效，還決定了上游供應商的需求、設施設計以及監管申報所需的分析開發深度。

終端用戶細分以切實的方式影響商業化和推廣策略。生物技術公司通常主導創新和平台開發，專注於智慧財產權的累積和臨床概念驗證。製藥公司則帶來後期開發、監管經驗和全球商業化基礎設施，一旦臨床證據和支付方證據一致，就能實現更廣泛的市場進入。醫院和診所在推廣需要特殊劑量、長期監測以及整合到現有診療路徑中的治療方法發揮著關鍵作用，它們的採購標準也越來越強調已證實的臨床效用和營運可行性。研究機構仍然是發現和轉化專業知識的重要來源，它們通常與產業界合作，以降低早期科學研究風險並加速新型平台的迭代。

綜上所述，這些細分洞察凸顯了在專案規劃早期階段協調治療標靶、給藥途徑和終端使用者參與策略的必要性。如果研發人員能夠明確考慮適應症特徵、平台限制和終端使用者需求之間的相互作用，就能更好地設計出符合監管預期並加速臨床應用的臨床試驗方案。

對美洲、歐洲、中東和非洲以及亞太地區的生態系統如何對創新、製造能力、監管合規性和准入策略產生不同影響進行全面的區域評估。

區域動態對RNA療法的研究、開發和商業化過程中的商業考量有不同的影響。在美洲，健全的創業投資生態系統、領先的學術醫療中心和先進的製造基礎設施為早期創新和快速臨床轉化提供了沃土。國家監管機構制定的監管路徑強調嚴格的安全性和有效性證據，而能夠對接專業契約製造製造商和服務供應商網路的計畫則能加快臨床試驗的進程。

歐洲、中東和非洲的管理體制和支付結構各不相同，因此需要製定細緻入微的市場准入計畫。歐洲的法規結構提倡集中核准管道，這有利於跨境核准，而該地區的醫療保健系統則強調成本效益和實際治療價值。亞太新興市場生物技術活動和臨床試驗參與度不斷提高，這為註冊和合作提供了機會，同時也需要協調一致的監管和報銷策略。

亞太地區的特點是生產能力快速擴張、公共和私人部門對生物製藥製造的大量投資，以及日益成長的熟練科學家和技術人員隊伍。多個地區正在積極簡化先進療法的監管流程，並鼓勵本土生產，從而加快本地研發計畫的進程。然而，對區域供應鏈的依賴以及監管協調程度的不均衡，要求企業採取多元化的採購方式，並積極與監管機構溝通，以確保專案在多個司法管轄區順利推進。

本文深入概述了平台領導、策略聯盟、製造專業化和監管參與如何構成RNA治療領域最有效組織的特徵。

在RNA療法領域領先的公司正透過平台深度、策略合作夥伴關係和生產能力的組合來脫穎而出。以平台為中心的創新者投資於基礎技術，以實現跨多個適應症的快速迭代，並優先考慮模組化設計、可靠的表徵方法以及支援監管討論的資料包封裝。具有競爭力的研發和生產公司正在拓展脂質奈米顆粒製劑、分析方法開發和無菌填充等專業服務，他們認知到，在應對複雜的RNA項目時，深厚的技術能力是競爭優勢。

合作模式已成為商務策略的核心。技術開發商與大型製藥公司之間的策略聯盟能夠匯集資源，用於後期研發和全球商業化；而學術界與臨床機構的夥伴關係能加速轉化研究，並為早期臨床試驗的患者提供便利。有些公司追求垂直整合，以確保關鍵投入並降低外部供應波動帶來的風險；而有些公司則專注於外吐小體分離或聚合物載體化學等細分領域，以提供獨特的價值提案。

在這一領域取得成功的公司中，卓越營運的重要性日益凸顯。那些早期投資於可擴展分析、穩健的流程控制和監管科學專業知識的公司，能夠更有效率地推進臨床開發，並更有信心與支付方進行溝通。此外，與監管機構和衛生技術評估機構建立暢通管道的公司，往往能夠減少核准阻力，並促進報銷談判。整體而言，業界更青睞那些在生產、監管和商業等各個環節都具備卓越科學領導力和實際執行能力的營業單位。

為高階主管提供以行動為導向的指導，內容涵蓋平台選擇、供應鏈韌性、監管溝通和商業化準備，以加速臨床影響。

為了將科學突破轉化為持續的治療效果，產業領導者必須採取務實、協作的行動，平衡創新與營運嚴謹性。應優先投資於與目標適應症相符的給藥平台，並確保製劑選擇既符合生物學原理，又符合下游生產的可行性。早期專案應包含分析方法開發和製程表徵，以最大限度地減少後期階段的意外情況，並加快從研究到GMP生產的過渡過程。

增強供應鏈韌性至關重要。企業應評估關鍵原料的雙重籌資策略，探索區域製造方案以降低跨境風險，並洽談長期合約以確保取得專用耗材。同時，企業應尋求與合約開發公司和學術中心建立策略合作夥伴關係，以降低技術障礙風險，並在產品組合決策中保持靈活性。

與監管機構、支付方和臨床相關人員的溝通應儘早開始，並持續迭代。研發人員應設計能夠捕捉監管機構和報銷方均關注的終點指標的臨床項目，並投資於能夠證明長期價值的真實世界證據基礎。最後，將臨床開發路徑與實際運作能力結合，有助於形成嚴謹的商業化方法，從而確保科學進步能大規模地惠及病患。

我們採用多學科調查方法，結合技術文獻綜述、監管機構分析、臨床註冊登記檢索和專家訪談，並以透明的方式說明，從而得出可靠的研究結果。

本研究綜合了來自同行評審的科學文獻、監管指導文件、臨床試驗註冊庫、專利概況、生產技術報告以及對行業高管、科學家和夥伴關係專家的訪談證據。透過資料來源的三角驗證，檢驗了技術趨勢、給藥平台的可行性以及營運限制，從而保持了分析的嚴謹性。定性訪談為決策流程、合作理由和生產考量提供了背景資訊，而二手資料則提供了歷史先例和監管演變的參考。

調查方法中採取了多項保障措施，包括由多位專家對技術聲明進行交叉檢驗，根據設施設計文件檢驗生產和配方方面的挑戰，以及仔細研讀監管條文以確保對核准流程的準確解讀。這種方法優先考慮揭露假設，並透過區分實踐模式和瞬時事件，著重關注與營運相關的持續趨勢。在整個研究過程中，我們專注於提供可操作的見解，而非推測性的預測，從而使從業人員能夠將研究結果直接應用於專案規劃和策略決策。

總結性結論強調，要充分發揮RNA技術的治療潛力，需要將科學創新、製造成熟度和相關人員的參與結合在一起。

RNA療法正曲折點，技術成熟、臨床應用目標不斷擴大以及監管預期不斷變化，三者匯聚，共同創造了巨大的轉化應用機會。持續進展不僅取決於分子設計和遞送方式的創新，還取決於企業執行複雜生產宣傳活動、管理供應鏈動態以及與整個醫療生態系統中的相關人員互動的能力。那些將卓越的科學研究實力與前瞻性的營運理念相結合的企業，將更有能力開發出滿足未被滿足的醫療需求的治療方法，同時克服商業化和市場准入方面的實際挑戰。

隨著這一領域的不斷發展，平台可重複性、終端用戶整合以及證據生成等方面的重點將決定哪些項目能夠成功進入臨床應用並產生持續的影響。未來幾年，融合分子生物學、製劑化學、製程工程和法規科學的多學科團隊將在將實驗室突破轉化為可靠、可擴展的患者療法方面擁有優勢。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新型脂質奈米顆粒製劑最佳化了罕見疾病mRNA疫苗的傳遞與穩定性
  • GalNAc偶聯siRNA療法的日益普及提高了肝病中標靶基因靜默的效率。
  • 增加對自擴增RNA平台的投資，以增強低劑量水準的抗原表現。
  • 基於CRISPR的RNA編輯技術的進步加速了體內基因突變的矯正。
  • 擴大分散式製造中心，以實現基於RNA的治療藥物的快速本地化生產
  • 開發耐熱mRNA疫苗製劑，以減少新興市場對低溫運輸的依賴
  • 生物製藥公司與人工智慧公司進行新合作，加速RNA序列設計與遞送載體最佳化。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 RNA療法市場：依治療領域分類

  • 心血管疾病
  • 遺傳性疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤
  • 罕見疾病
    • 高雪氏症
    • 神經肌肉疾病
    • 鐮狀細胞性貧血症

9. 依遞送系統分類的RNA療法市場

  • 外泌體
  • 脂質奈米顆粒
  • 聚合物載體
  • 病毒載體

第10章 以最終用戶分類的RNA療法市場

  • 生技公司
  • 醫院和診所
  • 製藥公司
  • 研究所

第11章：按地區分類的RNA療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：RNA療法市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：各國RNA療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Moderna, Inc.
    • BioNTech SE
    • Sarepta Therapeutics, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • CureVac NV
    • Arcturus Therapeutics Holdings, Inc.
    • Silence Therapeutics plc
    • Stoke Therapeutics
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market is projected to grow by USD 14.15 billion at a CAGR of 23.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.60 billion
Estimated Year [2025] USD 3.23 billion
Forecast Year [2032] USD 14.15 billion
CAGR (%) 23.55%

Comprehensive primer explaining how advancements in RNA modalities, delivery innovations, and regulatory evolution are converging to redefine therapeutic development pathways

The field of RNA therapeutics has moved from scientific curiosity to a central pillar of contemporary biomedicine, reshaping how researchers, clinicians, and industry leaders approach treatment discovery and development. Advances in messenger RNA, small interfering RNA, antisense oligonucleotides, and related modalities have demonstrated therapeutic potential across a wide spectrum of indications, stimulating renewed investment in platform technologies, delivery systems, and specialized manufacturing capabilities. This transition is reflected in accelerated translational pipelines, strategic collaborations between academic institutions and industry, and a growing emphasis on scalable, reproducible production processes.

Technological maturation has been matched by evolving regulatory expectations and clinical evidence requirements, prompting developers to refine trial designs, safety monitoring approaches, and comparator choices. Meanwhile, improvements in delivery vectors, formulation chemistry, and analytical methods have reduced barriers to entry for new developers while raising the bar for differentiation. Consequently, organizations now prioritize platform robustness, cross-indication applicability, and the ability to demonstrate consistent performance across diverse patient populations.

As stakeholders evaluate next steps, the industry must integrate scientific progress with pragmatic operational planning. Manufacturing capacity, supply chain resilience, and regulatory engagement are now as critical as target selection and preclinical efficacy. In short, RNA therapeutics sits at a pivotal juncture where scientific promise must be matched by execution excellence to translate into durable clinical and commercial outcomes.

Detailed analysis of how breakthroughs in delivery platforms, clinical prioritization, and business models are jointly reshaping the RNA therapeutics ecosystem and commercialization strategies

The landscape for RNA therapeutics is undergoing a sequence of transformative shifts that alter strategic priorities for developers and investors alike. First, delivery science has emerged as a primary differentiator: formulations based on lipid nanoparticles and emerging exosome platforms are enabling systemic delivery and tissue targeting that were previously elusive, while polymer carriers and viral vector hybrids offer complementary approaches for sustained expression or localized effect. These delivery advances expand the range of treatable indications, influence dosing paradigms, and materially affect manufacturing requirements.

Second, there is a clear reorientation of clinical focus toward complex and previously intractable indications. Oncology programs increasingly explore RNA-mediated modulation of tumor biology and immune activation for both hematological malignancies and solid tumors, while rare disease efforts harness gene-silencing and replacement strategies to address genetic disorders such as Gaucher disease, neuromuscular disorders, and sickle cell disease. Infectious disease applications, including targeted approaches for viral infections and novel antibacterial RNA strategies, retain strategic importance given global public health priorities and the capability of RNA platforms to accelerate response timelines.

Third, the business model is shifting as platform-centric companies seek to monetize broad technology stacks through licensing, strategic alliances, and vertical integration. Contract development and manufacturing organizations are expanding capabilities to service high-containment production and lipid nanoparticle encapsulation, and hospitals and clinics are beginning to engage with advanced therapies in new ways as clinical delivery paradigms evolve. Research institutes continue to feed innovation, creating a dynamic innovation pipeline that is increasingly interdependent across sectors.

Finally, heightened attention to regulatory and payer evidence is reshaping go-to-market strategies. Developers are investing in real-world evidence generation, longitudinal safety monitoring, and health economics studies that support reimbursement discussions and policy adoption. Taken together, these shifts signal a transition from discrete, proof-of-concept achievements to sustained, system-level integration of RNA therapeutics into clinical practice.

In-depth assessment of how tariff developments can alter supply chains, sourcing strategies, clinical prioritization, and manufacturing investments across RNA therapeutic programs

The potential imposition of cumulative tariffs originating from the United States in 2025 presents a complex set of operational and strategic challenges for organizations involved in RNA therapeutics. Tariff dynamics can increase landed costs for critical raw materials such as lipids, nucleotides, enzymes, and single-use consumables, and they can also affect the availability and pricing of high-value capital equipment used for plasmid production, microfluidic encapsulation, chromatography systems, and sterile fill-finish lines. When procurement costs rise, developers and contract manufacturers are pressured to reassess supplier relationships, inventory strategies, and sourcing geographies to preserve program timelines and maintain quality standards.

In response to tariff-driven cost pressures, companies may accelerate efforts to localize supply chains, expanding domestic production of key inputs or negotiating longer-term procurement agreements to stabilize pricing. While localization can reduce exposure to cross-border tariffs, it often requires significant capital investment and operational lead time, particularly when specialized manufacturing attributes or regulatory approvals are necessary. As a result, smaller developers and research institutes that lack in-house production capabilities may be disproportionately affected, compelling greater reliance on regional contract manufacturers and strategic partners.

Tariffs can also influence clinical development decisions. Increased input costs may cause sponsors to optimize trial designs to reduce material usage per patient, to prioritize indications with clearer pathways to reimbursement, or to sequence programs based on resource intensity. For hospitals and clinics, procurement budgets could be squeezed, potentially affecting adoption cycles for advanced therapies that require complex delivery or supportive infrastructure. Investors and strategic partners will therefore scrutinize the resilience of supply chain plans and the feasibility of production scale-up under altered cost structures.

Finally, the political and regulatory signaling associated with tariff policy can have reputational and strategic implications. Heightened trade tensions may encourage multinational firms to diversify manufacturing footprints across multiple regions to avoid exposure to single-jurisdiction policy shifts. At the same time, bilateral and multilateral dialogues can create pathways for exemptions or tariff mitigation mechanisms for critical healthcare supplies, underscoring the importance of active engagement with policymakers and industry associations. In short, tariff developments in 2025 could catalyze structural adjustments across procurement, manufacturing strategy, and clinical program prioritization, with tangible implications for timelines and partnership models.

Rigorous exploration of therapeutic area distinctions, delivery platform trade-offs, and end-user behaviors that together define program pathways and development priorities for RNA interventions

Segment-level dynamics reveal where scientific opportunity and commercial viability intersect, and they illuminate the tactical choices organizations must confront when advancing RNA-based interventions. Examining therapeutic area segmentation, developers are balancing broad applicability against indication-specific complexity: cardiovascular and metabolic disorder programs pursue systemic delivery and sustained activity, genetic disorder initiatives target precise gene correction or silencing for monogenic conditions, infectious disease strategies differentiate between bacterial approaches and viral infection countermeasures, neurological programs grapple with blood-brain barrier delivery constraints, oncology efforts split between hematological malignancies and solid tumors with differing immuno-oncology considerations, and rare disease pursuits concentrate on specific conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease where clinical endpoints and regulatory pathways demand bespoke evidence packages. This therapeutic heterogeneity drives divergent development timelines, safety considerations, and commercial access strategies.

When viewed through the lens of delivery system segmentation, contrasts become even more pronounced. Exosome-based strategies promise biologically native delivery and potential immune stealth but face manufacturing and characterization challenges that require advanced analytical capacity. Lipid nanoparticle technologies have become the de facto solution for many systemic applications due to demonstrated scalability and established regulatory precedents, yet they demand rigorous control of excipients and process parameters. Polymer carriers offer tunable release profiles and modular design but frequently require extensive biocompatibility validation, while viral vectors deliver robust transgene expression for certain applications at the cost of immunogenicity and complex regulatory scrutiny. The choice of delivery platform not only affects clinical performance but also determines upstream supplier needs, facility design, and the depth of analytical development required for regulatory submissions.

End-user segmentation shapes commercialization and adoption strategies in practical ways. Biotechnology companies often lead innovation and platform development, focusing on intellectual property creation and clinical proof of concept. Pharmaceutical companies bring late-stage development, regulatory experience, and global commercialization infrastructure, enabling broader market access when clinical and payer evidence align. Hospitals and clinics play a critical role in adoption for therapies that require specialized administration, long-term monitoring, or integration into existing care pathways, and their procurement criteria increasingly emphasize demonstrable clinical benefit and operational feasibility. Research institutes remain essential sources of discovery and translational expertise, frequently partnering with industry to de-risk early science and catalyze new platform iterations.

Taken together, these segmentation insights underscore the necessity of aligning therapeutic targets, delivery choices, and end-user engagement strategies early in program planning. Developers that explicitly account for the interplay among indication characteristics, platform constraints, and end-user requirements are better positioned to design clinical programs that meet regulatory expectations and accelerate acceptance in clinical practice.

Comprehensive regional appraisal of how Americas, EMEA, and Asia-Pacific ecosystems differentially influence innovation, manufacturing capacity, regulatory navigation, and access strategies

Regional dynamics shape the operational calculus for research, development, and commercialization of RNA therapies in distinct ways. In the Americas, robust venture capital ecosystems, leading academic medical centers, and advanced manufacturing infrastructure provide a fertile environment for early-stage innovation and rapid clinical translation. Regulatory pathways administered by national authorities emphasize rigorous safety and efficacy evidence, and the concentration of specialized contract manufacturers and service providers reduces time-to-clinic for programs that can access these networks.

Europe, the Middle East, and Africa present a mosaic of regulatory regimes and payer structures that require nuanced market access planning. The European regulatory framework promotes centralized review pathways that can support cross-border approvals, while health systems across the region emphasize cost-effectiveness and real-world therapeutic value. Emerging markets within the region are experiencing growing biotech activity and clinical trial participation, offering opportunities for enrollment and partnership but necessitating tailored regulatory and reimbursement strategies.

Asia-Pacific is characterized by rapid capacity expansion, substantial public and private investment in biopharmaceutical manufacturing, and an increasing number of skilled scientific and technical personnel. Several jurisdictions are actively streamlining regulatory processes for advanced therapies and incentivizing domestic production, which can accelerate timelines for locally developed programs. Nevertheless, regional supply chain dependencies and variable regulatory harmonization require companies to adopt diversified sourcing approaches and proactive regulatory engagement to ensure smooth program progression across multiple jurisdictions.

Insightful summary of how platform leadership, strategic alliances, manufacturing specialization, and regulatory engagement distinguish the most effective organizations in RNA therapeutics

Leading organizations operating in the RNA therapeutics domain differentiate themselves through a combination of platform depth, strategic partnerships, and manufacturing capabilities. Platform-centric innovators invest in foundational technologies that enable rapid iteration across multiple indications, prioritizing modular design, robust characterization methods, and data packages that support regulatory discussions. Contract developers and manufacturers are expanding specialized services for lipid nanoparticle formulation, analytical method development, and aseptic fill-finish, recognizing that deep technical capability is a competitive advantage when serving complex RNA programs.

Collaborative models have become central to business strategies. Strategic alliances between technology developers and larger pharmaceutical organizations enable resource pooling for late-stage development and global commercialization, while academic and clinical partnerships accelerate translational research and facilitate patient access for early trials. Some organizations pursue vertical integration to secure critical inputs and reduce exposure to external supply volatility, whereas others focus on niche specialization-such as exosome isolation or polymer carrier chemistry-to command unique value propositions.

Operational excellence is increasingly visible in the firms that succeed in this space. Companies that have invested early in scalable analytics, robust process controls, and regulatory science expertise move more efficiently through clinical development and engage payers more credibly. Additionally, those that cultivate open channels with regulators and health technology assessment bodies tend to reduce approval friction and achieve smoother reimbursement discussions. In aggregate, the industry favors entities that combine scientific leadership with pragmatic execution capabilities across manufacturing, regulatory, and commercial functions.

Action-oriented guidance for executives to align platform selection, supply chain resilience, regulatory engagement, and commercialization readiness to accelerate clinical impact

To convert scientific breakthroughs into sustainable therapeutic impact, industry leaders must adopt pragmatic, coordinated actions that balance innovation with operational rigor. Prioritize investment in delivery platforms that align with targeted indications, ensuring that formulation choices are justified by both biological rationale and downstream manufacturing feasibility. Early-stage programs should incorporate analytical development and process characterization to minimize late-stage surprises and to shorten timelines when transitioning from research to GMP production.

Strengthening supply chain resilience is essential. Companies should evaluate dual-sourcing strategies for critical raw materials, consider regional manufacturing options to mitigate cross-border policy exposure, and negotiate long-term agreements that secure access to specialized consumables. Simultaneously, organizations should pursue strategic collaborations with contract developers and academic centers to de-risk technical hurdles while maintaining flexibility in portfolio decision-making.

Engagement with regulators, payers, and clinical stakeholders must begin early and continue iteratively. Developers should design clinical programs that capture endpoints meaningful to both regulators and reimbursement authorities, and they should invest in real-world evidence infrastructures that demonstrate long-term value. Finally, cultivate a disciplined approach to commercialization by aligning clinical development pathways with realistic operational capabilities, thereby ensuring that scientific advances can be delivered reliably to patients at scale.

Transparent description of the multidisciplinary research approach combining technical literature review, regulatory analysis, clinical registry inspection, and primary expert interviews for robust insight generation

This research synthesizes evidence from peer-reviewed scientific literature, regulatory guidance documents, clinical trial registries, patent landscapes, manufacturing technology reports, and primary interviews with industry executives, scientists, and regulatory experts. Analytical rigor was maintained through triangulation across data sources to validate technology trends, delivery platform feasibility, and operational constraints. Qualitative interviews provided context on decision-making processes, partnership rationales, and manufacturing considerations, while secondary sources informed historical precedent and regulatory evolution.

Methodological safeguards included cross-validation of technical claims with multiple domain experts, verification of manufacturing and formulation challenges against facility design documentation, and careful attention to regulatory language to ensure accurate interpretation of approval pathways. The approach prioritized disclosure of assumptions and sought to isolate practice patterns from transient events, thereby focusing on durable trends with operational relevance. Throughout the study, emphasis was placed on actionable insight rather than speculative projection, enabling practitioners to apply findings directly to program planning and strategic decision-making.

Concluding synthesis emphasizing the necessity of combining scientific innovation, manufacturing maturity, and stakeholder engagement to realize the therapeutic potential of RNA technologies

RNA therapeutics stand at an inflection point where technological maturity, expanding clinical ambition, and evolving regulatory expectations converge to create substantial translational opportunity. Continued progress will depend not only on innovations in molecular design and delivery but equally on the ability of organizations to execute complex manufacturing campaigns, manage supply chain dynamics, and engage stakeholders across the healthcare ecosystem. Those that integrate scientific excellence with operational foresight will be positioned to advance therapies that address unmet medical needs while navigating the practical realities of commercialization and access.

As the field progresses, attention to platform reproducibility, end-user integration, and evidence generation will determine which programs achieve clinical adoption and sustained impact. The coming years will likely favor multidisciplinary teams that combine molecular biology, formulation chemistry, process engineering, and regulatory science to convert laboratory breakthroughs into reliable, scalable treatments for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of lipid nanoparticle formulations optimizing mRNA vaccine delivery and stability for rare diseases
  • 5.2. Growing adoption of GalNAc-conjugated siRNA therapeutics improving targeted gene silencing in liver disorders
  • 5.3. Increased investment in self-amplifying RNA platforms to enhance antigen expression at lower dose levels
  • 5.4. Advances in CRISPR-based RNA editing technologies accelerating in vivo correction of genetic mutations
  • 5.5. Expansion of decentralized manufacturing hubs enabling rapid regional production of RNA-based therapies
  • 5.6. Development of thermostable mRNA vaccine formulations reducing cold chain dependencies in emerging markets
  • 5.7. New collaborations between biopharma and AI firms to accelerate RNA sequence design and delivery vector optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Therapy Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
    • 8.3.1. Bacterial Infections
    • 8.3.2. Viral Infections
  • 8.4. Metabolic Disorders
  • 8.5. Neurological Disorders
  • 8.6. Oncology
    • 8.6.1. Hematological Malignancies
    • 8.6.2. Solid Tumors
  • 8.7. Rare Diseases
    • 8.7.1. Gaucher Disease
    • 8.7.2. Neuromuscular Disorders
    • 8.7.3. Sickle Cell Disease

9. RNA Therapy Market, by Delivery System

  • 9.1. Exosomes
  • 9.2. Lipid Nanoparticles
  • 9.3. Polymer Carriers
  • 9.4. Viral Vectors

10. RNA Therapy Market, by End User

  • 10.1. Biotechnology Companies
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. RNA Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Moderna, Inc.
    • 14.3.2. BioNTech SE
    • 14.3.3. Sarepta Therapeutics, Inc.
    • 14.3.4. Alnylam Pharmaceuticals, Inc.
    • 14.3.5. Ionis Pharmaceuticals, Inc.
    • 14.3.6. Arrowhead Pharmaceuticals, Inc.
    • 14.3.7. CureVac N.V.
    • 14.3.8. Arcturus Therapeutics Holdings, Inc.
    • 14.3.9. Silence Therapeutics plc
    • 14.3.10. Stoke Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 282. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 283. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 284. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 285. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 290. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 291. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 324. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 325. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 326. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 327. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 330. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 331. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 332. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 333. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. G7 RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 338. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 339. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 340. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 341. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 344. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 345. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 346. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 347. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 348. NATO RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 349. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 350. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 351. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 352. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 353. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 354. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 355. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 356. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 357. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)